SCHEMBL2903626

SCHEMBL2903626

CCCCCCCC(O)CCOS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2C Q5R387 1/20 0.44
MCHR1 Q99705 1/20 0.42
GPR84 Q9NQS5 4/20 0.40
ALDH1A1 P00352 2/20 0.39
FFAR4 Q5NUL3 1/20 0.39
FFAR1 O14842 1/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 2/20 0.39
CA1 P00915 1/20 0.39
CA4 P22748 1/20 0.39
CA7 P43166 1/20 0.39
NR1I2 O75469 1/20 0.38
NFKB1 P19838 1/20 0.38
MMP9 P14780 2/20 0.38
MMP13 P45452 2/20 0.38
ADAM17 P78536 2/20 0.38
CA12 O43570 1/20 0.38
MMP1 P03956 1/20 0.38
LMNA P02545 1/20 0.37
ALB P02768 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9465707 1.00 PLA2G2C (0.44) PLA2G2CMCHR1GPR84ALDH1A1FFAR4
SCHEMBL10792302 0.99 PLA2G2C (0.42) PLA2G2CMCHR1GPR84ALDH1A1FFAR4
SCHEMBL30721168 0.95 PLA2G2C (0.46) PLA2G2CMCHR1GPR84ALDH1A1FFAR4
SCHEMBL5474740 0.89 CA12 (0.44) PLA2G2CALDH1A1CA2CA9CA1
SCHEMBL4303888 0.89 CA12 (0.44) PLA2G2CALDH1A1CA2CA9CA1
SCHEMBL5477848 0.89 CA12 (0.44) PLA2G2CALDH1A1CA2CA9CA1
SCHEMBL5071377 0.88 PLA2G2C (0.45) PLA2G2CMCHR1GPR84ALDH1A1CA2
SCHEMBL13219933 0.88 PLA2G2C (0.45) PLA2G2CMCHR1GPR84ALDH1A1CA2
SCHEMBL9625787 0.88 PLA2G2C (0.45) PLA2G2CMCHR1GPR84ALDH1A1CA2
SCHEMBL9625505 0.88 PLA2G2C (0.45) PLA2G2CMCHR1GPR84ALDH1A1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7833993-B2 Immunomodulatory compounds and methods of use thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-11-16 US disclosed
EP-1439184-B1 Immunological adjuvant compounds EISAI R&D MAN CO LTD (JP) 2010-06-16 EP disclosed
US-7560584-B2 Immunomodulatory compounds and methods of use thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-07-14 US disclosed
US-20050164988-A1 Immunomodulatory compounds and methods of use thereof EISAI CO., LTD. (JP) 2005-07-28 US disclosed
US-20050123566-A1 Immunomodulatory compounds and methods of use thereof EISAI CO., LTD (JP) 2005-06-09 US disclosed
US-6835721-B2 Phosphate or ammonium compounds that function as immunological adjuvants when co-administered with antigens such as vaccines for bacterial and viral diseases EISAI CO., LTD. (JP) 2004-12-28 US disclosed
EP-1439184-A1 Immunological adjuvant compounds Eisai Co., Ltd. (JP) 2004-07-21 EP disclosed
EP-1147117-B1 IMMUNOLOGICAL ADJUVANT COMPOUNDS EISAI CO LTD (JP) 2004-06-16 EP disclosed
US-20040006242-A1 Immunomodulatory compounds and method of use thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-01-08 US disclosed
US-20030153532-A1 Immunomodulatory compounds and methods of use thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2003-08-14 US disclosed
US-6551600-B2 A phosphate derivative when co-administered with antigens such as vaccines for bacterial and viral diseases function as immunological adjuvant EISAI CO., LTD. (JP) 2003-04-22 US disclosed
US-20020176861-A1 Immunological adjuvant compounds compositions and methods of use thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2002-11-28 US disclosed
US-6290973-B1 VACCINES FOR BACTERIAL AND VIRAL DISEASES EISAI CO., LTD. (JP) 2001-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050123566-A1 Immunomodulatory compounds and methods of use thereof TLR5, TLR3, TLR6 PLA2G2C 230/4885MCHR1 2418/4885GPR84 756/4885
US-20020176861-A1 Immunological adjuvant compounds compositions and methods of use thereof TLR5, MYD88, TLR3 PLA2G2C 61/4885MCHR1 2944/4885GPR84 511/4885
US-20050164988-A1 Immunomodulatory compounds and methods of use thereof TSLP, IL5, ICOS PLA2G2C 600/4885MCHR1 2495/4885GPR84 704/4885
US-20040006242-A1 Immunomodulatory compounds and method of use thereof IL5, ICOS, TSLP PLA2G2C 679/4885MCHR1 2434/4885GPR84 789/4885
US-20030153532-A1 Immunomodulatory compounds and methods of use thereof TLR5, TLR3, TLR6 PLA2G2C 230/4885MCHR1 2418/4885GPR84 756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.